FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

These 15 PC games prove you don’t need massive storage for unforgettable adventures and all-time great gameplay.

“When the causative organism or agent of a disease, and its mode of transmission from one person to another hasn’t been ...

US-based HistoSonics has secured the first major insurance coverage for its histotripsy system, amid media speculation of a ...

KPN reports on progress of € 250m share buyback ...